Article
Cardiac & Cardiovascular Systems
Yihan Lin, Taylor J. Davis, Andres Zorrilla-Vaca, Brandon M. Wojcik, Shelley D. Miyamoto, Melanie D. Everitt, David N. Campbell, James J. Jaggers, T. Konrad Rajab
Summary: The study reviewed the outcomes of neonatal heart transplants at Children's Hospital Colorado over nearly 30 years. It found an early survival rate of 95.2%, with 1- and 5-year survival rates of 85.7% and 75%, respectively. Long-term follow-up at 10 and 20 years showed survival rates of 72.2% and 50%.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Daniel E. Clark, Ryan D. Byrne, Jeremy A. Mazurek, Alexander R. Opotowsky, Kelly H. Schlendorf, Meng Xu, Sandip Zalawadiya, Jonathan N. Menachem
Summary: This study found that in adults with congenital heart disease, donor sizing is not significantly associated with post-heart transplant survival, indicating that oversizing of donors does not improve mortality outcomes for these patients. The findings suggest that optimal donor sizing for heart transplantation in this population remains unclear.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Katherine Kearney, Edmund M. Lau, David Darley, Anitra Romfh, Nicole Bart, Eugene Kotlyar, Don Hayes, Kiran Khush, Anne Keogh
Summary: The study found that in the current era, ES-ASD or ES-VSD patients represented a decreasing proportion of all lung or heart-lung transplants compared to other indications. The odds of transplantation for ES-ASD and ES-VSD patients were significantly lower compared to other candidates for lung transplantation. In the early era, ES-ASD patients who underwent heart-lung transplants had equivalent survival rates to those who underwent lung transplants, while ES-VSD patients had superior survival rates.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)
Article
Immunology
Vojtech Petr, Dorottya Csuka, Petra Hruba, Agnes Szilagyi, Marek Kollar, Antonij Slavcev, Zoltan Prohaszka, Ondrej Viklicky
Summary: De novo thrombotic microangiopathy (TMA) is associated with poor kidney graft survival, and there is a recipient-driven process with suspected genetic background. Carriers of the MCPggaac haplotype have a higher risk of graft loss, and longer cold ischemia time is associated with worse graft survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Editorial Material
Hematology
Anthony Sabulski, Sonata Jodele
Summary: Transplant-associated thrombotic microangiopathy is a life-threatening complication of haematopoietic stem cell transplant, and some patients do not respond to current treatment methods. Qi et al. show that HIF-1α may be a previously unrecognized driver of this endothelial injury syndrome.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Asma Khan, Elfriede Pahl, Devin A. Koehl, Ryan S. Cantor, James K. Kirklin, Paolo Rusconi, Aliessa P. Barnes, Estela Azeka, Melanie D. Everitt
Summary: Patients with heterotaxy have lower post-transplant survival rates and are more susceptible to infection and severe rejection. However, mortality risk associated with heterotaxy is mitigated in the recent transplant era.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)
Article
Urology & Nephrology
Kelly A. Birdwell, Meyeon Park
Summary: Cardiovascular disease remains a major cause of death and hospitalization in kidney transplant recipients. Identifying and treating cardiovascular risk factors, as well as exploring emerging therapies like sodium-glucose cotransporter 2 inhibitors, are crucial in post-transplant care. Future research areas include setting goals for risk factor management, utilizing biomarkers, and improving screening and intervention strategies.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Immunology
Nikolaus Kneidinger, Christina Valtin, Ina Hettich, Bjorn Christian Frye, Alexandra Wald, Heinrike Wilkens, Vasiliki Bessa, Jens Gottlieb
Summary: This study analyzed the effectiveness of an everolimus-based quadruple low calcineurin inhibitor (CNI) regimen compared to a standard triple regimen in patients who underwent lung transplantation. The results showed that there was no significant difference in renal function between the two regimens, but the quadruple low CNI regimen had a higher incidence of thromboembolic events. There was a trend towards higher survival rates for chronic lung allograft dysfunction in the quadruple low CNI regimen. Overall, the everolimus-based quadruple low CNI regimen appeared to be comparable to the standard triple regimen in terms of immunosuppressive efficacy and safety.
Article
Cardiac & Cardiovascular Systems
Christopher R. Broda, Rafael Alonso-Gonzalez, Anand Ghanekar, Aliya Gulamhusein, Michael McDonald, Adriana Luk, Jeremy Kobulnik, Filio Billia, Jane Heggie, Marjan Jariani, Osami Honjo, David Barron, Edward Hickey, Susan L. Roche
Summary: Adult Fontan patients with failing Fontan circulation can achieve favorable mid-term outcomes after heart transplant, with non-progression of FALD, resolution of ascites, and freedom from hepatocellular carcinoma.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Cardiac & Cardiovascular Systems
Charles A. Herzog, Mengistu A. Simegn, Yifan Xu, Salvatore P. Costa, Roy O. Mathew, Mohammad C. El-Hajjar, Sanjeev Gulati, Rafael A. Maldonado, Eric Daugas, Magdelena Madero, Jerome L. Fleg, Rebecca Anthopolos, Gregg W. Stone, Mandeep S. Sidhu, David J. Maron, Judith S. Hochman, Sripal Bangalore
Summary: In the ISCHEMIA-CKD study, an invasive strategy did not show improved outcomes compared to conservative management in kidney transplant candidates. These findings do not recommend routine coronary angiography or revascularization for patients with advanced CKD and chronic coronary syndromes listed for transplant.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Hematology
Ambreen Pandrowala, Parth Ganatra, V. P. Krishnan, Ajay Narayan Sharma, Saroj Chavan, Minnie Bodhanwala, Bharat Agarwal, Prashant Hiwarkar
Summary: TA-TMA is an endothelial injury syndrome linked to the overactivation of complement pathways. Inhibition of the lectin pathway with Narsoplimab can be effective in treating TA-TMA.
THROMBOSIS JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Arene Butto, Chad Y. Mao, Lydia Wright, Martha Wetzel, Michael S. Kelleman, Michael P. Carboni, Anne I. Dipchand, Kenneth R. Knecht, Zdenka Reinhardt, Joshua D. Sparks, Chet Villa, William T. Mahle
Summary: A longer duration of VAD support prior to HTx is associated with a one-year survival benefit in children, although questions of patient complexity, post-VAD complications, and the impact on causality remain.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Cardiac & Cardiovascular Systems
Noah Weingarten, Amit Iyengar, David Alan Herbst, Mark Helmers, David Rekhtman, Cindy Song, Samuel T. Kim, Pavan Atluri
Summary: In obese patients with non-dialysis-dependent kidney disease, simultaneous heart-kidney transplant (HKT) may decrease long-term mortality compared to isolated heart transplant (IHT), and should be strongly considered as a preferred treatment.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Article
Medicine, General & Internal
Marie Nagai, Takahiro Uchida, Muneharu Yamada, Shuuhei Komatsu, Kohei Ota, Mitsuya Mukae, Hitoshi Iwamoto, Hiroshi Hirano, Miho Karube, Shinya Kaname, Takashi Oda
Summary: A 57-year-old man who had received a kidney transplant developed TAFRO syndrome, which led to thrombocytopenia and ultimately death, despite treatment with high-dose steroids and other measures. Pathological analysis of kidney tissues showed similarities to his pre-transplant condition, suggesting recurrence of TAFRO syndrome.
FRONTIERS IN MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Ioanna Lazana
Summary: Transplant-associated thrombotic microangiopathy (TA-TMA) is a significant contributor to morbidity and mortality after allogenic hematopoietic stem cell transplantation (allo-HSCT). The diagnosis of TA-TMA is challenging due to lack of consensus diagnostic criteria and common clinical features mimicking other diseases. Therapeutic plasma exchange (TPE) has been traditionally used, but the efficacy is doubtful. Complement inhibitors, such as eculizumab, have shown promising results in clinical trials. Future goals include identifying specific risk factors and developing better treatment options.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)